Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entinostat With or Without Anlotinib + Fulvestrant in HR+/HER2- Advanced Breast Cancer
NCT07330544Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Nov 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of entinostat, anlotinib in breast cancer, sponsored by Zhejiang Cancer Hospital. Started Nov 2025; status: recruiting.
02
Drugs
entinostatanlotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07330544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07330544.